Show simple item record

dc.contributor.authorRobles-Zurita, J
dc.contributor.authorBoyd, KA
dc.contributor.authorBriggs, AH
dc.contributor.authorIveson, T
dc.contributor.authorKerr, RS
dc.contributor.authorSaunders, Mark P
dc.contributor.authorCassidy, J
dc.contributor.authorHollander NH
dc.contributor.authorTabernero, J
dc.contributor.authorSegelov, E
dc.contributor.authorGlimelius, B
dc.contributor.authorHarkin, A
dc.contributor.authorAllan, K
dc.contributor.authorMcQueen, J
dc.contributor.authorPearson, S
dc.contributor.authorWaterston, A
dc.contributor.authorMedley, L
dc.contributor.authorWilson, C
dc.contributor.authorEllis, R
dc.contributor.authorEssapen, S
dc.contributor.authorDhadda, AS
dc.contributor.authorHughes, R
dc.contributor.authorFalk, S
dc.contributor.authorRaouf, S
dc.contributor.authorRees, C
dc.contributor.authorOlesen, RK
dc.contributor.authorPropper, D
dc.contributor.authorBridgewater, J
dc.contributor.authorAzzabi, A
dc.contributor.authorFarrugia, D
dc.contributor.authorWebb, A
dc.contributor.authorCunningham, D
dc.contributor.authorHickish, T
dc.contributor.authorWeaver, A
dc.contributor.authorGollins, S
dc.contributor.authorWasan, HS
dc.contributor.authorPaul J
dc.date.accessioned2018-12-10T11:48:54Z
dc.date.available2018-12-10T11:48:54Z
dc.date.issued2018en
dc.identifier.citationRobles-Zurita J, Boyd KA, Briggs AH, Iveson T, Kerr RS, Saunders MP, et al. SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. Br J Cancer. 2018 Nov;119(11):1332-8.en
dc.identifier.pmid30420616en
dc.identifier.doi10.1038/s41416-018-0319-zen
dc.identifier.urihttp://hdl.handle.net/10541/621407
dc.description.abstractBACKGROUND: The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3?M) versus the usually given 6 months (6?M) of adjuvant chemotherapy in colorectal cancer. METHODS: In total, 6088 patients with fully resected high-risk stage II or stage III colorectal cancer were randomised and followed up for 3-8 years. The within-trial cost-effectiveness analysis from a UK health-care perspective is presented using the resource use data, quality of life (EQ-5D-3L), time on treatment (ToT), disease-free survival after treatment (DFS) and overall survival (OS) data. Quality-adjusted partitioned survival analysis and Kaplan-Meier Sample Average Estimator estimated QALYs and costs. Probabilistic sensitivity and subgroup analysis was undertaken. RESULTS: The 3?M arm is less costly (-£4881; 95% CI: -£6269; -£3492) and entails (non-significant) QALY gains (0.08; 95% CI: -0.086; 0.230) due to a better significant quality of life. The net monetary benefit was significantly higher in 3?M under a wide range of monetary values of a QALY. The subgroup analysis found similar results for patients in the CAPOX regimen. However, for the FOLFOX regimen, 3?M had lower QALYs than 6?M (not statistically significant). CONCLUSIONS: Overall, 3?M dominates 6?M with no significant detrimental impact on QALYs. The results provide the economic case that a 3?M treatment strategy should be considered a new standard of careen
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41416-018-0319-zen
dc.titleSCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant oxaliplatin combination chemotherapy for colorectal cancer.en
dc.typeArticleen
dc.contributor.departmentInstitute of Health and Wellbeing, University of Glasgow, Glasgow, UKen
dc.identifier.journalThe British Journal of Canceren
refterms.dateFOA2020-04-22T12:31:17Z


Files in this item

Thumbnail
Name:
560902.pdf
Size:
434.5Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record